Detection and susceptibility testing of Mycoplasma amphoriforme isolates from patients with respiratory tract infections

Clin Microbiol Infect. 2010 Jul;16(7):1007-9. doi: 10.1111/j.1469-0691.2009.02993.x. Epub 2009 Jul 15.

Abstract

Three isolates of Mycoplasma amphoriforme, a new Mycoplasma species rarely described to date, were obtained from respiratory tract specimens from two children and one adult with respiratory tract infections. Molecular methods were required to distinguish them from Mycoplasma pneumoniae. MICs of macrolides, tetracyclines and fluoroquinolones were identical to those for M. pneumoniae, except for that of ciprofloxacin, which was slightly more potent against M. amphoriforme. M. amphoriforme could possibly have been involved in one case of severe respiratory infection with sepsis, but further studies are needed to specify its role as a potential respiratory tract pathogen.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Child
  • DNA, Bacterial / analysis
  • DNA, Bacterial / genetics
  • Fluoroquinolones / pharmacology
  • Humans
  • Macrolides / pharmacology
  • Male
  • Microbial Sensitivity Tests
  • Mycoplasma / classification
  • Mycoplasma / drug effects*
  • Mycoplasma / isolation & purification*
  • Mycoplasma / metabolism
  • Mycoplasma Infections / drug therapy
  • Mycoplasma Infections / microbiology*
  • Polymerase Chain Reaction
  • Respiratory Tract Infections / drug therapy
  • Respiratory Tract Infections / microbiology*
  • Tetracyclines / pharmacology

Substances

  • Anti-Bacterial Agents
  • DNA, Bacterial
  • Fluoroquinolones
  • Macrolides
  • Tetracyclines